Spinal Cord Stimulation Devices Market (2026 - 2033)

Spinal Cord Stimulation Devices Market Summary

The global spinal cord stimulation devices market size was valued at USD 3.2 billion in 2025 and is projected to grow from USD 3.4 billion in 2026 to USD 5.8 billion in 2033, at a CAGR of 7.4% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 30.0% in 2025. The spinal cord stimulator, known as the dorsal column stimulator, is an implanted device for managing chronic pain through a neuromodulator. The device prevents the brain from feeling pain by sending electric signals that interfere with pain signals. The rise in chronic pain cases, the aging population, technological improvements, and increased awareness are the main drivers of growth in the spinal cord stimulation devices market. Chronic pain is a prevalent affliction that impacts millions of individuals globally.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The increasing occurrence of chronic pain conditions, including failed back surgery syndrome, complex regional pain syndrome, and neuropathic pain, significantly increases the need for spinal cord stimulation devices. With the growing aging population in the world, there is also a rise in age-related health problems such as degenerative disc disease and other spinal issues that frequently necessitate the use of spinal cord stimulation devices. Elderly individuals have a higher likelihood of developing chronic pain conditions, which has increased the need for efficient methods of pain management.

Technological advancements in spinal cord stimulation devices also contribute to the surge in demand. Innovations such as improved battery life, wireless technology, and more precise stimulation settings have enhanced the efficacy and convenience of these devices. Moreover, newer devices allow for greater customization and adjustments based on individual patient needs, which can lead to better pain management outcomes. The increasing availability of minimally invasive implantation procedures has made these devices more accessible, reducing recovery time and associated risks and further driving their adoption.

In addition, the growing body of clinical evidence supporting the effectiveness of spinal cord stimulation in managing chronic pain has led to broader acceptance within the medical community. As a result, insurance companies are more likely to cover the costs of these devices, making them a viable option for a broader range of patients. This combination of clinical validation, improved technology, and expanding insurance coverage fuels the global demand for spinal cord stimulation devices.

Furthermore, the rising awareness of non-opioid pain management solutions amid the opioid crisis has pushed both patients and healthcare providers to seek alternative treatments. Spinal cord stimulation offers a promising solution for managing pain without the risks associated with long-term opioid use, which is increasingly important in the current healthcare landscape. This shift towards safer, more sustainable pain management options is expected to continue driving the demand for spinal cord stimulation devices globally.

Analyst Perspective

The spinal cord stimulation devices market is experiencing steady growth, driven by the increasing prevalence of chronic pain disorders, rising demand for minimally invasive pain management solutions, and growing adoption of neuromodulation technologies. The use of spinal cord stimulators to treat chronic back pain, neuropathic pain, and failed back surgery syndrome through the delivery of specific electrical impulses has become common among healthcare providers. Advancements in rechargeable implantable devices, wireless programming, MRI-compatible systems, and closed-loop stimulation technologies are enhancing treatment effectiveness and patient outcomes. With increasing demand for safer, personalized, and long-lasting pain management techniques, companies that concentrate on innovations in technology and clinical research will be in a better position to capitalize on the growth opportunities in the future.

Product Insights

The rechargeable segment held the largest market revenue share of over 80.0% in 2025. Rechargeable spinal cord stimulation (SCS) systems provide longer battery life and allow clinicians to adjust stimulation parameters according to patients' therapeutic needs, reducing the frequency of replacement surgeries and improving long-term patient outcomes. Their compact battery design also enhances patient comfort and device usability. For instance, in December 2025, the U.S. Food and Drug Administration (FDA) approved Boston Scientific's PMA supplement (P030017/S374), expanding the MRI labeling for the WaveWriter Alpha and WaveWriter Alpha Prime spinal cord stimulator systems to include 3 Tesla MRI conditional access, increasing imaging compatibility for patients with rechargeable neurostimulation devices.

The non-rechargeable segment is projected to grow significantly during the forecast period. Technological advancements have improved battery longevity, miniaturization, and stimulation capabilities, making non-rechargeable spinal cord stimulators an effective option for many patients. These devices reduce maintenance requirements while delivering reliable long-term therapy, particularly for patients who prefer not to recharge implanted devices.

Application Insights

The complex regional pain syndrome (CRPS) segment accounted for the largest market revenue share in 2025. The increasing recognition and diagnosis of CRPS following trauma or surgery continue to drive demand for spinal cord stimulation as an effective therapy for chronic neuropathic pain. Improvements in neuromodulation technology are also expanding treatment options for patients with refractory pain conditions.

The degenerative disc disease (DDD) segment is expected to witness the fastest CAGR during the forecast period. The increasing prevalence of age-related spinal degeneration, obesity, and sedentary lifestyles continues to drive demand for minimally invasive pain management solutions. For instance, in March 2024, Abbott announced the expansion of its recharge-free BurstDR spinal cord stimulation technology in Canada, becoming the first and only recharge-free SCS system in the country capable of providing personalized dosing through the NeuroSphere Digital Care platform. The expansion strengthens access to advanced neuromodulation therapy for patients with chronic back and leg pain associated with degenerative spinal disorders.

Regional Insights

North America spinal cord stimulation devices market held the largest market revenue share of around 30.0% in 2025. The rising incidence of chronic pain disorders, including failed back surgery syndrome, complex regional pain syndrome (CRPS), and neuropathic pain, continues to drive demand for spinal cord stimulation devices in the region. Growing preference for minimally invasive pain management therapies over conventional surgical interventions, coupled with continuous technological advancements in neuromodulation, further supports market growth.

To learn more about this report, Download Free Sample Report

U.S. Spinal Cord Stimulation Devices Market Trends

The U.S. held the largest regional market share in 2025. The opioid crisis has accelerated the adoption of non-opioid pain management therapies, with spinal cord stimulation emerging as an important treatment option for patients with chronic pain. Increasing prevalence of degenerative disc disease, failed back surgery syndrome, and other chronic pain disorders among the aging population continues to support market growth. In addition, favorable regulatory pathways and continued innovation in neuromodulation technologies are expanding patient access to advanced spinal cord stimulation systems.

Europe Spinal Cord Stimulation Devices Market Trends

Europe spinal cord stimulation devices market is expected to witness steady growth during the forecast period. The increasing prevalence of diabetic neuropathy, spinal cord injuries, and chronic neuropathic pain, together with strong investments in medical technology, continues to drive demand for advanced neuromodulation therapies.

The UK spinal cord stimulation devices market is projected to grow significantly over the forecast period owing to the increasing prevalence of chronic pain among the aging population and growing awareness of non-opioid pain management therapies. Continued adoption of innovative neuromodulation technologies within the National Health Service (NHS) and specialized pain management centers is expected to support market expansion.

Asia Pacific Spinal Cord Stimulation Devices Market Trends

Asia Pacific is projected to register the fastest CAGR during the forecast period. Rapid population aging, increasing prevalence of chronic pain disorders, expanding healthcare infrastructure, and improving access to advanced neuromodulation therapies are driving market growth. Governments and healthcare providers across the region are investing in advanced medical technologies to improve pain management outcomes, while rising medical tourism in countries such as India and Thailand is further supporting demand.

The India spinal cord stimulation devices market is projected to witness significant growth over the forecast period. Rising incidence of chronic pain disorders, expansion of private healthcare facilities, and increasing adoption of advanced pain management technologies are improving access to spinal cord stimulation therapies.

Key Spinal Cord Stimulation Devices Company Insights

Some of the key companies in the spinal cord stimulation devices market include Boston Scientific Corporation; Medtronic; NeuroSigma, Inc.; Nevro Corp.; Synapse Biomedical Inc.; and others.

• Synapse Biomedical Inc. offers the NeuRx Diaphragm Pacing System (DPS), a cutting-edge spinal cord stimulator designed to aid patients with spinal cord injuries and amyotrophic lateral sclerosis (ALS). The system includes PermaLoc electrodes implanted in the diaphragm, which are connected to an external pulse generator (EPG) that sends electrical signals to stimulate natural breathing.
• Boston Scientific Corporation provides a variety of spinal cord stimulation (SCS) devices aimed at managing chronic pain. Their key products include the Precision Montage MRI, which allows for full-body MRI scans and delivers multiple waveforms for pain relief, and the Spectra WaveWriter, which personalizes pain relief through combination therapy and waveform automation. 

Key Spinal Cord Stimulation Devices Companies

The following are the leading companies in the spinal cord stimulation devices market. These companies collectively hold the largest market share and dictate industry trends.

• Boston Scientific Corporation

• Medtronic

• Saluda Medical Pty Ltd

• Nevro Corp

• Nalu Medical Inc

• Abbott

• GIMER MEDICAL

• Mainstay Medical

• Beijing Pinchi Medical Equipment Co., Ltd.

• SceneRay Co., Ltd.

Recent Developments

• In July 2025, Boston Scientific received U.S. FDA approval for new percutaneous spinal cord stimulation (SCS) leads, expanding its SCS portfolio with the industry's broadest range of lead configurations to support personalized chronic pain therapy.

• In February 2025, Saluda Medical announced the presentation of clinical data at the 2025 North American Neuromodulation Society (NANS) Annual Meeting. The company presented results from 11 abstracts and four oral presentations, including first-in-human data for its EVA automated spinal cord stimulation (SCS) programming platform and additional evidence supporting the clinical benefits of its Evoke ECAP-controlled closed-loop SCS system.

Global Spinal Cord Stimulation Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global spinal cord stimulation devices market report by product, application, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Rechargeable

  • Non-rechargeable

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Failed Back Syndrome

  • Complex Regional Pain Syndrome

  • Degenerative Disk Disease

  • Unsuccessful Disk Surgery

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait